Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. MDWD
MDWD logo

MDWD Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Mediwound Ltd (MDWD) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
15.300
1 Day change
1.69%
52 Week Range
22.500
Analysis Updated At
2026/03/27
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Mediwound Ltd (MDWD) is not a strong buy at this time for a beginner investor with a long-term strategy. The technical indicators are bearish, the financial performance shows significant revenue decline, and there are no positive catalysts or strong trading signals to justify an immediate investment. It is better to wait for clearer signs of growth or positive momentum before considering an entry.

Technical Analysis

The technical indicators for MDWD are bearish. The MACD is negatively expanding below zero (-0.0841), the RSI is neutral at 24.052, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below key support levels, with the current pre-market price of $15.71 below the pivot level of $16.712.

Options Data

Bullish
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio

The high Option Volume Put-Call Ratio (19.14) indicates a strong bearish sentiment in the options market, with significantly more put volume compared to call volume.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
9
Buy
3

Positive Catalysts

  • NULL identified. There is no recent news, no significant insider or hedge fund activity, and no recent congress trading data.

Neutral/Negative Catalysts

  • The financial performance in 2025/Q4 shows a significant revenue drop (-68.03% YoY) and a decline in gross margin (-3.69% YoY). Additionally, the bearish technical indicators and weak options sentiment further weigh against the stock.

Financial Performance

In 2025/Q4, revenue dropped significantly by 68.03% YoY to $1,867,000. However, net income improved to -$7,183,000 (up 83.80% YoY), and EPS increased to -0.56 (up 55.56% YoY). Gross margin declined to 14.89%, down 3.69% YoY. Overall, the financials indicate weak revenue growth but some improvement in profitability metrics.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst rating or price target changes are available for MDWD.

Wall Street analysts forecast MDWD stock price to rise
6 Analyst Rating
Wall Street analysts forecast MDWD stock price to rise
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 15.050
sliders
Low
25
Averages
30
High
36
Current: 15.050
sliders
Low
25
Averages
30
High
36
H.C. Wainwright
Buy
maintain
$31 -> $36
AI Analysis
2025-11-21
Reason
H.C. Wainwright
Price Target
$31 -> $36
AI Analysis
2025-11-21
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on MediWound to $36 from $31 and keeps a Buy rating on the shares. The company's new manufacturing facility with six-fold increased capacity is on track to begin commercial production in mid-2026, the analyst tells investors in a research note.
Oppenheimer
Oppenheimer
Outperform
to
Outperform
downgrade
$36 -> $34
2025-06-02
Reason
Oppenheimer
Oppenheimer
Price Target
$36 -> $34
2025-06-02
downgrade
Outperform
to
Outperform
Reason
Oppenheimer assumed coverage of MediWound with an Outperform rating with a price target of $34, down from $36. The firm notes the company's Q1 update highlighted progress across its clinical and commercial programs. Global EscharEx Phase 3 VALUE trial recruitment is underway, with most U.S. sites open, and interim data expected mid-2026. Given design similarities to Phase 2, Oppenheimer views Phase 3 as significantly derisked. MediWound's strategic collaborations and overall key opinion leader enthusiasm further validate EscharEx's clinical/commercial potential, the firm adds.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for MDWD
Unlock Now

People Also Watch